REFERENCES
  1. Zempsky WT, Loiselle KA, McKay K, et al. Retrospective evaluation of pain assessment and treatment for acute vasoocclusive episodes in children with sickle cell disease. Pediatr Blood Cancer 2008;51:265-268.
  2. Collins JJ, Grier HE, Kinney HC, et al. Control of severe pain in children with terminal malignancy. J Pediatr 1995;126:653-657.
  3. R3 Report: Pain assessment and management standards for hospitals. Issue 11, August 29, 2017. www.jointcommission.org
  4. Finkel JC, Pestieau SR, Quezado ZM. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. J Pain 8:515-521.
  5. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep. 2016;65:1-49.
  6. Field JJ. Five lessons learned about long-term pain management in adults with sickle cell disease. Hematology Am Soc Hematol Educ Program 2017;406-411.
  7. Zhu H, Brodsky M, Gorman AL, Inturrisi CE. Region-specific changes in NMDA receptor mRNA induced by chronic morphine treatment are prevented by the co-administration of the competitive NMDA receptor antagonist LY274614. Brain Res Mol Brain Res 2003;114:154-162.
  8. Ketamine pharmacology: An update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther 2013;19:370-380.
  9. Courade M, Bertrand A, Guerrini-Rousseau L, et al. Low-dose ketamine adjuvant treatment for refractory pain in children, adolescents and young adults with cancer: A pilot study. BMJ Support Palliat Care 2019;1-8.
  10. Kajiume T, Sera Y, Nakanuno R, et al. Continuous intravenous infusion of ketamine and lidocaine as adjuvant analgesics in a 5-year-old patient with neuropathic cancer pain. J Palliat Med 2012;15:719-722.
  11. White MC, Hommers C, Parry S, Stoddart PA. Pain management in 100 episodes of severe mucositis in children. Paediatr Anaesth 2011;21:411-416.
  12. James PJ, Howard RF, Williams DG. The addition of ketamine to a morphine nurse- or patient-controlled analgesia infusion (PCANCA) increases analgesic efficacy in children with mucositis pain. Paediatr Anaesth 2010;20:805-811.
  13. Conway M, White N, St. Jean C, Zempsky WT, Steven K. Use of continuous intravenous ketamine for end-stage cancer pain in children. J Pediatr Onc Nurs 2009;26:100-106.
  14. Anghelescu DL, Oakes LL. Ketamine use for reduction of opioid tolerance in a 5-year-old girl with end-stage abdominal neuroblastoma. J Pain Symptom Manage 2005;30:P1-P3.
  15. Tsui BC, Davies D, Desai S, Malherbe S. Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma. J Pediatr Hematol Oncol 2004;26:678-680.
  16. Klepstad P, Borchgrevink P, Hval B, Flaat S, Kaasa S. Long-term treatment with ketamine in a 12-year-old girl with severe neuropathic pain caused by a cervical spinal tumor. J Pediatr Hematol Oncol 2001;23:616-619.
  17. Fine PG. Low-dose ketamine in the management of opioid non-responsive terminal cancer pain. J Pain Symptom Manage 1999;17:296-300.
  18. Nobrega R, Sheehy KA, Lippold C, Rice AL, Finkel JC, Quezado ZM. Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease. Pediatr Res 2018;83:445-454.
  19. Neri CM, Pestieau SR, Young H, Elmi A, Finkel JC, Darbari DS. Low-dose ketamine for children and adolescents with acute sickle cell disease related pain: a single center experience. J Anesth Clin Res 2014;5:394-398.
  20. Tawfic AQ, Faris AS, Kausalya R. The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease. J Pain Symptom Manage 2014;47:334-340.
  21. Zempsky W, Loiselle KA, Corsi JM, Hagstrom NJ. Use of low-dose ketamine infusion for pediatric patients with sickle cell disease-related pain: a case series. Clin J Pain 2010;26:163-167.
  22. Masaracchia MM, Sites BD, Lee J, Thomas JJ, Fernandez PG. Subanesthetic ketamine infusions for the management of pediatric pain in non-critical care settings: An observational analysis. Acta Anaesthesiologica Scandinavica 2019;63:1225-1230.
  23. Sheehy KA, Muller EA, Lippold C, Nouraie M, Finkel JC, Quezado ZM. Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: A longitudinal study. BMC Pediatr 2105;15:198.
  24. Rowbotham MC. What is a “clinically meaningful” reduction in pain? Pain 2001;94:131-132.
  25. Cepeda MS, Africano JM, Polo R, Alcala R, Carr DB. What decline in pain intensity is meaningful to patients with acute pain? Pain 2003;105:151-157.
  26. Farrar JT, Young Jr. JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-158.
  27. Myrvik MP, Brandow AM, Drendel AL, et al. Clinically meaningful measurement of pain in children with sickle cell disease. Pediatr Blood Cancer 2013;60:1689-1695.
  28. Brandow AM, DeBaun MR. Key components of pain management for children and adults with sickle cell disease. Hematol Oncol Clin North Am 2018;32:535-550.
  29. Hardy J, Quinn S, Fazekas B, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 2012;30:3611-3617.
  30. Jackson K, Franco M, William L, et al. Ketamine and cancer pain: the reports of my death have been greatly exaggerated. J Clin Oncol 2013;31:1373-1374
  31. Bredlau AL, Thakur R, Korones DN, Dworkin RH. Ketamine for pain in adults and children with cancer: A systematic review and synthesis of the literature. Pain Med 2013;14:1505-1517.
Supporting Material: Ketamine infusion management protocol